home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 08/05/20

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen Therapeutics Announces Closing of $12.5 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif. , Aug. 5, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the closing of its pre...
VTGN - LD Micro Announces Preliminary List of Presenters for the LD-500

LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online. "For the first time in ten years, we were unable to host our mid-year conference, which ...

VTGN - EverInsight pays $5M upfront license payment to VistaGen

VistaGen Therapeutics ( VTGN ) receives $5M non-dilutive upfront license payment from EverInsight Therapeutics, the Company's partner for development and commercialization of PH94B for anxiety-related disorders in Asia. More news on: VistaGen Therapeutics, Inc., Healthcare stocks ne...

VTGN - VistaGen Therapeutics Announces Receipt of $5 Million Non-Dilutive Upfront License Payment from EverInsight Therapeutics for PH94B Strategic Collaboration

SOUTH SAN FRANCISCO, Calif. and SHANGHAI , Aug. 4, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced r...
VTGN - VistaGen prices equity offering at $0.80

VistaGen Therapeutics ( OTC:VTGN ) has priced its public offering of 15,625,000 common shares at $0.80/share, for expected gross proceeds of $12.5M. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Read more ...

VTGN - VistaGen Therapeutics Announces Pricing of $12.5 Million Underwritten Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , Aug. 2, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced the pricing of its und...

VTGN - VistaGen under pressure on proposed public offering

VistaGen Therapeutics  (NASDAQ: VTGN )   -14%  AH  commenced an underwritten public offering of shares. More news on: VistaGen Therapeutics, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

VTGN - VistaGen clarifies design of late-stage study of lead candidate in anxiety disorder

Based on FDA feedback, VistaGen (NASDAQ: VTGN ) has clarified key aspects of its planned Phase 3 clinical trial evaluating lead drug PH94B, a rapid-onset neurosteroid nasal spray, for the acute treatment of anxiety in adults with social anxiety disorder (SAD), a Fast Track-tagged indicat...

VTGN - VistaGen Therapeutics Announces Positive Meeting with FDA Regarding Pivotal Phase 3 Study of PH94B for Acute Treatment of Anxiety in Patients with Social Anxiety Disorder

SOUTH SAN FRANCISCO, Calif. , July 23, 2020 /PRNewswire/ --  VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, announced the results of a positive meeti...

VTGN - VistaGen Therapeutics reports FY results

VistaGen Therapeutics (NASDAQ: VTGN ): FY GAAP EPS of -$0.50. More news on: VistaGen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Previous 10 Next 10